S
Simon P. Fletcher
Researcher at Hoffmann-La Roche
Publications - 56
Citations - 3191
Simon P. Fletcher is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Hepatitis B virus & Immune system. The author has an hindex of 25, co-authored 56 publications receiving 2656 citations. Previous affiliations of Simon P. Fletcher include La Roche College & University of Cambridge.
Papers
More filters
Journal ArticleDOI
A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initation of hepatitis C and classical swine fever virus RNAs
Tatyana V. Pestova,Ivan N. Shatsky,Simon P. Fletcher,Richard J. Jackson,Christopher U.T. Hellen +4 more
TL;DR: Initiation of translation of hepatitis C virus and classical swine fever virus mRNAs results from internal ribosomal entry and the striking similarities between this eukaryotic initiation mechanism and the mechanism of translation initiation in prokaryotes are discussed.
Journal ArticleDOI
Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor
Adrien Decorsiere,Henrik Mueller,Pieter C van Breugel,Fabien Abdul,Laetitia Gerossier,Rudolf K. F. Beran,Christine M. Livingston,Congrong Niu,Simon P. Fletcher,Olivier Hantz,Michel Strubin +10 more
TL;DR: A novel role for the Smc5/6 complex as a restriction factor selectively blocking extrachromosomal DNA transcription is uncovered, and HBx relieves the inhibition to allow productive hepatitis B virus gene expression.
Journal ArticleDOI
Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection
Yves Horsmans,Thomas Berg,Jean-Pierre Desager,Tobias Mueller,Eckart Schott,Simon P. Fletcher,Kevin R. Steffy,Lisa A Bauman,Bradley M. Kerr,Averett Devron R +9 more
TL;DR: Systemic administration of the selective TLR7 agonist isatoribine resulted in dose‐dependent changes in immunologic biomarkers and a statistically significant antiviral effect with relatively few and mild side effects.
Journal ArticleDOI
Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B
Stephan Menne,Daniel B. Tumas,Katherine H. Liu,Linta M. Thampi,Dalal AlDeghaither,Baldwin Bh,Christine A. Bellezza,Paul J. Cote,Jim Zheng,Randall L. Halcomb,Abigail Fosdick,Simon P. Fletcher,Stephane Daffis,Li Li,Peng Yue,Grushenka H.I. Wolfgang,Bud C. Tennant +16 more
TL;DR: The data demonstrate that short duration, finite treatment with the oral TLR7 agonist GS-9620 can induce a sustained antiviral response in the woodchuck model of CHB, and support investigation of this compound as a therapeutic approach to attain a functional cure in CHB patients.
Journal ArticleDOI
PD-1 blockade partially recovers dysfunctional virus–specific B cells in chronic hepatitis B infection
Loghman Salimzadeh,Loghman Salimzadeh,Nina Le Bert,Charles-A. Dutertre,Charles-A. Dutertre,Upkar S. Gill,Evan W. Newell,Christian R. Frey,Magdeleine Hung,Nikolai Novikov,Simon P. Fletcher,Patrick T F Kennedy,Antonio Bertoletti,Antonio Bertoletti +13 more
TL;DR: HBV infection has a marked impact on global and HBV-specific humoral immunity, yet HBsAg-specific B cells are amenable to a partial rescue by B cell–maturing cytokines and PD-1 blockade.